BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test
product to the reference product in adult patients with asthma.
Phase:
Phase 3
Details
Lead Sponsor:
Cipla Ltd.
Treatments:
Fluticasone Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance